Investigational drug · Phase 3
MY008211A
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN).
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
12
Any phase or sponsor naming "MY008211A"
First trial start
2024
Aug 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MY008211A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Paroxysmal Nocturnal Hemoglobinuria
- IgA Nephropathy (IgAN)
- Paroxysmal Nocturnal Haemoglobinuria (PNH)
Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "MY008211A" as an intervention, largest first.
- Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal HemoglobinuriaPivotal-lookingRecruiting
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT06933914 · 120 participants (planned) · Start Nov 30, 2024 · Primary completion Dec 30, 2026
Drug: MY008211A tablets · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Tianjin, China
- Efficacy and Safety of Lanoracopan in the Treatment of PNHNot yet recruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT07788105 · 90 participants (planned) · Start Sep 2026 · Primary completion Dec 2028
Drug: Lanoracopan Hydrochloride · For: Paroxysmal Nocturnal Hemoglobinuria, PNH
- Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)Not yet recruiting
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT06687174 · 72 participants (planned) · Start Dec 31, 2024 · Primary completion Jun 15, 2026
Drug: MY008211A tablets; MY008211A tablets matched placebo · For: IgA Nephropathy (IgAN)
Sites: Beijing, China
- Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyPivotal-lookingRecruiting
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT06932744 · 66 participants (planned) · Start Aug 30, 2024 · Primary completion Dec 30, 2025
Drug: MY008211A tablets; Eculizumab Injection · For: Paroxysmal Nocturnal Haemoglobinuria (PNH)
Sites: Beijing, China; Tianjin, China
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT05642585 · 63 participants · Start May 27, 2022 · Primary completion Jun 4, 2023
Drug: MY008211A tablets; Placebo · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Changsha, China
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT05828472 · 40 participants · Start Jan 10, 2023 · Primary completion Jun 30, 2023
Drug: MY008211A tablets; MY008211A tablets matched placebo · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Changsha, China
- Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Not yet recruiting
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT06134414 · 40 participants (planned) · Start Dec 2025 · Primary completion Jul 2027
Drug: MY008211A tablets · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT06050226 · 34 participants · Start Jul 6, 2023 · Primary completion Apr 30, 2024
Drug: MY008211A tablets · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT07625618 · 24 participants · Start Sep 20, 2024 · Primary completion Dec 28, 2024
Drug: MY008211A tablets · For: Hepatic Insufficiency (MeSH ID: D048550)
Sites: Jilin City, China
- Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody TreatmentPivotal-lookingRecruiting
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT06932471 · 20 participants (planned) · Start Aug 30, 2024 · Primary completion Dec 30, 2025
Drug: MY008211A tablets · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.